Positron emission tomography imaging of tau pathology in progressive supranuclear palsy

Journal of Cerebral Blood Flow and Metabolism

Volumn 37, Issue 9, 2017, Pages 3150-3160

  Coakeley, Sarah ^a   Cho, Sang Soo ^a   Koshimori, Yuko ^a   Rusjan, Pablo ^a   Harris, Madeleine ^a   Ghadery, Christine ^a   Kim, Jinhee ^a   Lang, Anthony E ^a   Wilson, Alan ^a   Houle, Sylvain ^a   Strafella, Antonio P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Brain imaging; movement disorder; neuropathology; Parkinson s disease; positron emission tomography

Indexed keywords

BIOLOGICAL MARKER; FLORTAUCIPIR F 18; TAU PROTEIN; TRACER; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; CARBOLINE DERIVATIVE; FLUORINE;

AGED; ARTICLE; BECK DEPRESSION INVENTORY; BRAIN REGION; CASE REPORT; CEREBELLUM CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MONTREAL COGNITIVE ASSESSMENT; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIRED HELICAL FILAMENT; PARKINSON DISEASE; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROGRESSIVE SUPRANUCLEAR PALSY RATING SCALE; SCORING SYSTEM; TAUOPATHY; UNIFIED PARKINSON DISEASE RATING SCALE; BRAIN; CASE CONTROL STUDY; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROTEINOSIS;

AGED; BRAIN; CARBOLINES; CASE-CONTROL STUDIES; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN AGGREGATION, PATHOLOGICAL; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 85028597582     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1177/0271678X16683695     Document Type: Article

References (39)

1. Golbe L. The tau of PSP: a long road to treatment. Mov Disord 2014; 29: 431–434.
2. Liscic RM, Srulijes K, Gröger A, Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools. Acta Neurol Scand 2013; 127: 362–370.
3. Litvan I, Agid Y, Calne D, Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47: 1–9.
4. Golbe LI. Progressive supranuclear palsy. Semin Neurol 2014; 34: 151–159.
5. Kobylecki C, Jones M, Thompson J, Cogntive-behavioural features of progressive supranuclear palsy syndrome overlap with frontotemporal dementia. J Neurol 2015; 262: 916–922.
6. Osaki Y, Ben-Shlomo Y, Lees AJ, Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 2004; 19: 181–189.
7. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet 2009; 373: 2055–2066.
8. Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999; 246: II6–II15.
9. Avila J, Lucas JJ, Perez M, Role of tau protein in both physiological and pathological conditions. Physiol Rev 2004; 84: 361–384.
10. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013; 12: 609–622.
11. Iqbal K, Liu F, Gong C-X, Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 2010; 7: 656–664.
12. Shahani N, Brandt R. Functions and malfunctions of the tau proteins. Cell Mol Life Sci 2002; 59: 1668–1680.
13. Avila J, Lucas J. Role of tau protein in both physiological and pathological conditions. Physiol Rev 2004; 34: 361–384.
14. Noble W, Hanger DP, Miller CCJ, The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol 2013; 4: 88.
15. Thal DR, Attems J, Ewers M. Spreading of amyloid, tau, and microvascular pathology in Alzheimer’s disease: findings from neuropathological and neuroimaging studies. J Alzheimer’s Dis 2014; 42: 421–429.
16. Grijalvo-Perez A, Litvan I. Corticobasal degeneration. Semin Neurol 2014; 34: 160–173.
17. Kepe V, Bordelon Y, Boxer A, PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers Dis 2013; 36: 145–153.
18. Okamura N, Furumoto S, Harada R, Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 2013; 54: 1420–1427.
19. Okamura N, Furumoto S, Fodero-Tavoletti MT, Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain 2014; 137: 1762–1771.
20. Okamura N, Furumoto S, Harada R, In vivo selective imaging of tau pathology in Alzheimer’s disease with 18F-THK5117. J Nucl Med 2014; 55: 18–19.
21. Maruyama M, Shimada H, Suhara T, Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79: 1094–1108.
22. Xia CF, Arteaga J, Chen G, [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement 2013; 9: 666–676.
23. Marquie M, Normandin MD, Vanderburg CR, Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015; 78: 787–800.
24. Sander K, Lashley T, Gami P, Characterization of tau positron emission tomography tracer [18F] AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other dementias. Alzheimers Dement 2016; 12: 1116–1124.
25. Chien DT, Bahri S, Szardenings AK, Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013; 34: 457–468.
26. Schwarz AJ, Yu P, Miller BB, Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 2016; 139: 1539–1500.
27. Golbe L, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007; 130: 1552–1565.
28. Goetz CG, Tilley BC, Shaftman SR, Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129–2170.
29. Shoup TM, Yokell DL, Rice PA, A concise radiosynthesis of the tau radiopharmaceutical, [ 18F]T807. J Label Compd Radiopharm 2013; 56: 736–740.
30. Talairach J and Tournoux P. Co-planar stereotaxic atlas of the human brain. 3-dimensioanl proportional system: an approach to cerebral imaging. New York: Thieme Medical Publishers, 1988
31. Kabani N, Collins D and Evans A. A 3d neuroanatomical atlas. In: 4th international conference on functional mapping of the human brain, Montreal, Quebec, Canada, 7–12 June 1988, pp.7–12. Montreal: Organization for Human Brain Mapping
32. Rusjan P, Mamo D, Ginovart N, An automated method for the extraction of regional data from PET images. Psychiatry Res 2006; 147: 79–89.
33. Williams DR, Holton JL, Strand C, Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain 2007; 130: 1566–1576.
34. Brett M, Anton JL, Valabregue R, Region of interest analysis using the MarsBar toolbox for SPM 99. Neuroimage 2002; 16: S497.
35. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med 1998; 39: 904–911.
36. Giordano A, Tessitore A, Corbo D, Clinical and cognitive correlations of regional gray matter atrophy in progressive supranuclear palsy. Park Relat Disord 2013; 19: 590–594.
37. Massey LA, Micallef C, Paviour DC, Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord 2012; 27: 1754–1762.
38. Spillantini MG, Bird TD, Ghetti B. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol 1998; 8: 387–402.
39. 18F]AV-1451) in human subjects. J Nucl Med 2016; 807: 1–27.